Health & Nutrition
Jim Cramer highlights 5 investing themes — and the stocks...
CNBC’s Jim Cramer said earnings season reinforced five investing themes he thinks...
Sen. Mitch McConnell says he's left rehab, will work from...
"On the advice of my doctors, I'll maintain an intensive regimen of physical therapy...
CAMP4 advances rare disease treatment for SYNGAP1 into...
CAMP4 is preparing a Phase 1/2 trial of an experimental SYNGAP1 therapy, marking...
The divide between Eli Lilly and Novo Nordisk is widening...
As Lilly widens its lead in the obesity race, Novo is still racing to win back market...
The Benefits and Risks of Hair Loss Drugs
What are the pros and cons of Propecia and Rogaine for hair loss? “Any consumer...
AstraZeneca may buck a decade of pharma strategy to buy...
Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved...
Bank of America spends $250 million a year on GLP-1 drugs...
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and...
CVS blows past estimates, hikes guidance as insurance unit...
CVS also announced a new collaboration with Eli Lilly that will make Zepbound and...
Novo Nordisk CEO defends economics of Wegovy pill as lower...
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable...
Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli...